Kazuhide Nakamura Selected Research

N- (2- chloro- 4- ((6,7- dimethoxy- 4- quinazolinyl)oxy)phenyl)- N'- propylurea

1/2006	Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window.
12/2004	KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kazuhide Nakamura Research Topics

Disease

12	Neoplasms (Cancer) 01/2018 - 12/2004
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 01/2017
2	Leukemia 01/2017 - 01/2017
2	Colonic Neoplasms (Colon Cancer) 01/2017 - 03/2008
2	Carcinoma (Carcinomatosis) 03/2008 - 03/2005
2	Pathologic Neovascularization 09/2006 - 12/2004
2	Body Weight (Weight, Body) 03/2005 - 12/2004
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2017
1	Carcinogenesis 06/2013
1	Ascites 03/2008
1	Hyperplasia 09/2006
1	Rheumatoid Arthritis 09/2006
1	Arthritis (Polyarthritis) 09/2006
1	T-Cell Leukemia (Leukemia, T Cell) 09/2006
1	Inflammation (Inflammations) 09/2006
1	Weight Loss (Weight Reduction) 01/2006
1	Melanoma (Melanoma, Malignant) 03/2005
1	Glioma (Gliomas) 03/2005

Drug/Important Bio-Agent (IBA)

6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 12/2004
4	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 12/2013 - 12/2004
4	Phosphotransferases (Kinase)IBA 12/2013 - 09/2006
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2013 - 09/2006
3	tivozanibIBA 03/2008 - 09/2006
2	AntibodiesIBA 01/2018 - 01/2017
2	Panitumumab (Vectibix)FDA Link 01/2018 - 01/2017
2	Tyrosine (L-Tyrosine)FDA Link 06/2013 - 09/2006
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 09/2006 - 12/2004
2	N- (2- chloro- 4- ((6,7- dimethoxy- 4- quinazolinyl)oxy)phenyl)- N'- propylureaIBA 01/2006 - 12/2004
1	Bevacizumab (Avastin)FDA Link 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Biological ProductsIBA 01/2018
1	trifluridine tipiracil drug combinationIBA 01/2017
1	T-3775440IBA 01/2017
1	ChromatinIBA 01/2017
1	Lysine (L-Lysine)FDA Link 01/2017
1	Transcription Factors (Transcription Factor)IBA 01/2017
1	Trifluridine (Viroptic)FDA LinkGeneric 01/2017
1	N- (4- ((2- ((cyclopropylcarbonyl)amino)imidazo(1,2- a)pyridin- 6- yl)oxy)- 3- fluorophenyl)- 6- methyl- 2- oxo- 1- phenyl- 1,2- dihydropyridine- 3- carboxamideIBA 06/2013
1	LigandsIBA 06/2013
1	Proto-Oncogene Proteins c-metIBA 06/2013
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2013
1	TAK 593IBA 04/2013
1	PDGF receptor tyrosine kinaseIBA 04/2013
1	Tyrosine Kinase InhibitorsIBA 03/2008
1	Therapeutic UsesIBA 03/2008
1	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 09/2006
1	Proteins (Proteins, Gene)FDA Link 01/2006
1	Pharmaceutical PreparationsIBA 01/2006
1	LC 6IBA 03/2005

Therapy/Procedure

4	Oral Administration 06/2013 - 03/2005
1	Drug Therapy (Chemotherapy) 01/2018
1	Therapeutics 01/2018
1	Transplantation 03/2008
1	Withholding Treatment 12/2004